文献速递乳腺癌

Palbociclib治疗激素受体阳性晚期乳腺癌的成本-效用分析

Palbociclib in hormone receptor positive advanced breast cancer: A cost-utility analysis.
PubMed 文献 · Eur J Cancer · 2017-09-18

该研究从加拿大医疗支付方视角评估palbociclib联合letrozole一线治疗激素受体阳性晚期乳腺癌的成本-效用,采用概率离散事件模拟模型,参数来源于PALOMA 1和2试验等。结果显示,与单用letrozole相比,联合palbociclib每获得一个质量调整生命月需增量成本161,508加元,增量成本-效用比为10,999加元/QALM。在支付意愿阈值为4,167加元/QALM时,palbociclib具有成本-效用的概率为0%。作者认为,按当前价格,该方案在加拿大医疗体系下不太可能具有成本-效用。

要点

  • 与单用letrozole相比,联合palbociclib增加14.7个质量调整生命月,增量成本为161,508加元。
  • 增量成本-效用比为10,999加元/QALM。
  • 在支付意愿阈值为4,167加元/QALM时,palbociclib具有成本-效用的概率为0%。

核心结论

  • 从加拿大医疗支付方视角,按当前价格,在letrozole基础上加用palbociclib治疗晚期乳腺癌不太可能具有成本-效用。
  • 尽管晚期乳腺癌患者从palbociclib获得了有意义的临床获益,但应考虑提高支付意愿阈值并降低药品价格,以使该策略更可负担。

研究设计与样本

  • 研究采用概率离散事件模拟模型,参数来源于PALOMA 1和2试验及其他来源。
  • 基础 case 采用15年时间跨度,成本和效果按每年5%贴现。
  • 进展时间和死亡时间分别从Weibull分布和指数分布推导。
  • 期望成本基于安大略省收费标准及其他来源。
  • 进行了概率敏感性分析以考虑参数不确定性。

主要发现

  • 与单用letrozole相比,加用palbociclib额外获得14.7个质量调整生命月,增量成本为161,508加元。
  • 增量成本-效用比为10,999加元/QALM。
  • 假设支付意愿阈值为4,167加元/QALM,palbociclib具有成本-效用的概率为0%。
  • 概率敏感性分析得出的成本-效用可接受曲线显示,在支付意愿阈值为11,000加元/QALM时,palbociclib具有成本-效用的概率为50%。

关键数值与推荐

  • 增量成本-效用比为10,999加元/QALM。
  • 在支付意愿阈值为4,167加元/QALM时,palbociclib具有成本-效用的概率为0%。
  • 在支付意愿阈值为11,000加元/QALM时,palbociclib具有成本-效用的概率为50%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The addition of palbociclib to letrozole improves progression-free survival in the first-line treatment of hormone receptor positive advanced breast cancer (ABC). This study assesses the cost-utility of palbociclib from the Canadian healthcare payer perspective. METHODS: A probabilistic discrete event simulation (DES) model was developed and parameterised with data from the PALOMA 1 and 2 trials and other sources. The incremental cost per quality-adjusted life-month (QALM) gained for palbociclib was calculated. A time horizon of 15 years was used in the base case with costs and effectiveness discounted at 5% annually. Time-to- progression and time-to-death were derived from a Weibull and exponential distribution. Expected costs were based on Ontario fees and other sources. Probabilistic sensitivity analyses were conducted to account for parameter uncertainty. RESULTS: Compared to letrozole, the addition of palbociclib provided an additional 14.7 QALM at an incremental cost of $161,508. The resulting incremental cost-effectiveness ratio was $10,999/QALM gained. Assuming a willingness-to-pay (WTP) of $4167/QALM, the probability of palbociclib to be cost-effective was 0%. Cost-effectiveness acceptability curves derived from a probabilistic sensitivity analysis showed that at a WTP of $11,000/QALM gained, the probability of palbociclib to be cost-effective was 50%. CONCLUSION: The addition of palbociclib to letrozole is unlikely to be cost-effective for the treatment of ABC from a Canadian healthcare perspective with its current price. While ABC patients derive a meaningful clinical benefit from palbociclib, considerations should be given to increase the WTP threshold and reduce the drug pricing, to render this strategy more affordable.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Raphael J, Helou J, Pritchard KI, et al. Palbociclib in hormone receptor positive advanced breast cancer: A cost-utility analysis. Eur J Cancer. 2017. PMID: 28930692. doi:10.1016/j.ejca.2017.08.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。